Features  |   November 2018
Challenges to VAD Deactivation
Article Information
Cardiovascular Anesthesia / Palliative Care / End-of-Life Care / Features
Features   |   November 2018
Challenges to VAD Deactivation
ASA Monitor 11 2018, Vol.82, 28-30.
ASA Monitor 11 2018, Vol.82, 28-30.
Mechanical cardiac support (MCS) devices started with pacemakers (PMs), expanded to intracardiac defibrillators (ICDs) and now include ventricular assist devices (VADs) as well as total artificial hearts (TAHs). While each has become accepted as therapy, deactivation requests from patients or appropriate surrogates have been less well received. Legal and ethical objections to deactivation have been raised with each device. It is reasonably well settled in the United States that deactivation of PMs and ICDs is an acceptable medical action. This consensus is based on respect for patient-centered determination of burdens and benefits of a therapy, which can change as the patient experiences life with the device as well as develops additional pathologies.
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Affiliation & Institution
I have a potential conflict of interest
Comment Title

This feature is available to Subscribers Only
ASA Member Login or Create an Account ×